An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Condition:   Angelman Syndrome Intervention:   Drug: NNZ-2591 Sponsor:   Neuren Pharmaceuticals Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials